週三，雅培實驗室 (NYSE:ABT) 報告第四季度銷售額爲109.7億美元，同比增長7.2%，低於市場預期的110.1億美元。基礎業務有機銷售增長爲8.8%，剔除COVID-19檢測相關銷售的有機增長爲10.1%。調整後的每股攤薄收益爲1.34美元，與分析師預期及管理層共識1.31-1.37美元一致，高於去年同期的1.19美元。雅培主席兼首席執行官羅伯特·福特表示，“我們在年內取得了強勁的勢頭。第四季度的銷售增長和每股收益增長是全年最高的。”醫療器械銷售增長13.7%，達到50.5億美元，有機增長爲14%。糖尿病護理方面，連續血糖監測儀的銷售額爲18億美元，報告增長22.7%，有機增長22.8%。全球COVID-19檢測銷售在2024年第四季度爲1.76億美元，而去年同期爲2.88億美元。剔除COVID-19檢測相關銷售，全球診斷銷售增長4.3%（有機增長6.1%）。雅培預計2025年全年調整後每股收益爲5.05-5.25美元，市場共識爲5.16美元，有機銷售增長爲7.5%-8.5%，調整後經營利潤率爲23.5%-24.0%。公司預計2025年第一季度調整後每股收益爲1.05-1.09美元，市場共識爲1.11美元。

以上內容來自Benzinga Earnings專欄，原文如下：

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.

Organic sales growth for the underlying base business was 8.8%. Organic growth, excluding COVID-19 testing-related sales was 10.1%.

Adjusted diluted earnings per share were $1.34, in line with the analyst estimates and management consensus of $1.31-$1.37, up from $1.19 a year ago.

Also Read: FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch

“We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year,” said Robert Ford, chairman and chief executive officer.

“We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.”

Medical Device sales increased 13.7% to $5.05 billion and 14% organically, including double-digit growth in the U.S. and internationally.

Several products contributed, including FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet, and AVEIR.

In Diabetes Care, sales of continuous glucose monitors were $1.8 billion and grew 22.7% on a reported basis and 22.8% organically.

Nutrition sales increased by 4.5% to $2.07 billion (+7.1% organically). In Pediatric Nutrition, global sales increased by 1.5% (+2.5%), reflecting continued market share gains in the infant formula business. Adult nutrition sales increased 7.4% (+11.4%), led by the Ensur and Glucerna brands.

Worldwide COVID-19 testing sales were $176 million in the fourth quarter of 2024 compared to $288 million a year ago. Excluding COVID-19 testing-related sales, global Diagnostics sales increased 4.3% (+6.1%). Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests.

Guidance: Abbott projects full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.16, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%.

Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05-$1.09 versus consensus of $1.11.

Price Action: ABT stock is up 0.72% at $117.64 at the last check Wednesday.

Read Next:

• Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook

Photo by Sundry Photography via Shutterstock